Search
Search Results
-
Characterization of immunomodulatory factors and cells in bronchoalveolar lavage fluid for immune checkpoint inhibitor-related pneumonitis
As immune checkpoint inhibitors (ICIs) are widely used, a series of immune-related adverse events (irAEs) have been reported, including immune...
-
Differences in the risk of immune-related pneumonitis between PD-1 and PD-L1 inhibitors: a meta-analysis according to the new mirror-principle and PRISMA guidelines
PurposeTo compare the risk of immune-associated pneumonitis between PD-1 and PD-L1 inhibitors, the meta-analysis was designed.
Method ...
-
Treatment patterns and outcomes of high-grade immune checkpoint inhibitor-related pneumonitis in an oncology hospitalist service
PurposeImmune checkpoint inhibitors (ICI) have become standard of care for some types of lung cancer. Along with expanding usage comes the emergence...
-
Risk factors of immune checkpoint inhibitor-related pneumonitis after neoadjuvant immunochemotherapy for resectable NSCLC
BackgroundThe incidence of checkpoint inhibitor-associated pneumonitis (CIP) in advanced non-small cell lung cancer (NSCLC) has been substantiated...
-
Immune checkpoint inhibitor-related pneumonitis and COVID-19: a case-matched comparison of CT findings
ObjectivesTo compare the radiological findings of immune checkpoint inhibitor-related pneumonitis (IRP) and COVID-19 pneumonia, evaluating the...
-
Clinical outcomes and risk factor of immune checkpoint inhibitors-related pneumonitis in non-small cell lung cancer patients with chronic obstructive pulmonary disease
Objectives:Chronic obstructive pulmonary disease (COPD) is the most common co-morbidity associated with non-small cell lung cancer (NSCLC) patients....
-
Association of pre-existing lung interstitial changes with immune-related pneumonitis in patients with non-small lung cancer receiving immunotherapy
Background and aimMany pieces of literature have evaluated the predictive value of pre-existing lung interstitial changes for immunotherapy-related...
-
Checkpoint Inhibitor-Induced Pneumonitis: Incidence and Management
Purpose of ReviewDespite immune checkpoint inhibitors’ (ICIs) many notable benefits, they carry the risk of immune-related adverse events (irAEs)....
-
Immune-Related Adverse Events in Patients with Lung Cancer
Purpose of ReviewImmune checkpoint inhibitors (ICI) have been widely adopted for the treatment of lung cancer since receiving first U.S Food and Drug...
-
Second-line immunosuppressant administration for steroid-refractory immune-related adverse events in patients with lung cancer
BackgroundEvidence for use of second-line immunosuppressants for immune-related adverse events (irAEs) is inadequate. Therefore, a multicenter...
-
Clinical implications of bronchoscopy for immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer
BackgroundThe utility of bronchoscopy for patients with suspected immune checkpoint inhibitor (ICI)-related pneumonitis is currently debatable. The...
-
A potential mechanism of the onset of immune-related pneumonitis triggered by anti-PD-1 treatment in a patient with advanced adenocarcinoma lung cancer: case report
BackgroundIn recent years, the application of immunotherapy combined with chemotherapy in the first-line lung cancer has showed significant benefit...
-
Deciphering pathogenic cellular module at single-cell resolution in checkpoint inhibitor-related pneumonitis
Checkpoint inhibitor pneumonitis (CIP) is the most common fatal immune-related adverse event; however, its pathophysiology remains largely unknown....
-
Value of 2-[18F]FDG-PET/CT in identifying immune-related adverse events in patients with melanoma or non-small cell lung cancer: a systematic sco** review
PurposeWe aimed provide overview of the current literature regarding the diagnostic accuracy of 2-[ 18 F]FDG-PET/CT in detecting immune-related...
-
Hypersensitivity Pneumonitis: A Silent Epidemic?
Purpose of ReviewHypersensitivity pneumonitis (HP), along with interstitial lung disease as a whole, is a disorder with rising incidence, morbidity,...
-
Association between pre-treatment chest imaging and pulmonary function abnormalities and immune checkpoint inhibitor pneumonitis
BackgroundImmune checkpoint inhibitors (ICIs) are a first-line treatment for various metastatic solid tumors. Pneumonitis is a potentially...
-
Immune-related adverse events after immune checkpoint inhibitor exposure in adult cancer patients with pre-existing autoimmune diseases
PurposeImmune checkpoint inhibitor (ICI) therapy can predispose patients to immune-related adverse events (irAEs) and autoimmune disease (AD)...
-
Systematic surveillance of immune-related adverse events in clinical practice and impact of subsequent steroid medication on survival outcomes
BackgroundRecent advances in immune-checkpoint inhibitors (ICIs) have highlighted the need for effective management of immune-related adverse events...
-
Clinical Issue of Myasthenia Gravis Related to Immune Checkpoint Inhibitors
Abstract Purpose of ReviewImmune-related adverse events (irAEs) are pivotal in the management of immune checkpoint inhibitors (ICIs) across various...
-
A Risk-Scoring Model for Severe Checkpoint Inhibitor-Related Pneumonitis: A Case–Control Study
Background and ObjectiveCheckpoint inhibitor-related pneumonitis (CIP) is one of the most common serious and fatal adverse events associated with...
